AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18848937 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 48
Study 18848937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15942734 — intervention group
Group type: EXPERIMENTAL
Intervention: Prep (low intensity electrical shock)
Number of subjects: 12
Study 15942734 — intervention group
Group type: EXPERIMENTAL
Intervention: Start (loud auditory stimulus)
Number of subjects: 12
Study 15942734 — intervention group
Group type: EXPERIMENTAL
Intervention: PrepStart (combination of Prep and Start)
Number of subjects: 12
Study 15942734 — intervention group
Group type: COMPARATOR
Intervention: React (imperative signal for execution of the reaction)
Number of subjects: 12
Study 15942734 — intervention group
Group type: EXPERIMENTAL
Intervention: PrepReact (Prep followed by React)
Number of subjects: 12
Study 15942734 — intervention group
Group type: EXPERIMENTAL
Intervention: StartReact (Start followed by React)
Number of subjects: 12
Study 15942734 — intervention group
Group type: EXPERIMENTAL
Intervention: PrepStartReact (Prep followed by StartReact)
Number of subjects: 12
Study 12000246 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita-Stat 90550 automated device
Number of subjects: 108
Study 12000246 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron HEM-705CP automated device
Number of subjects: 108
Study 12000246 — intervention group
Group type: COMPARATOR
Intervention: Sphygmomanometer
Number of subjects: 108
Study 10730908 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks (T12)
Number of subjects: 496
Study 10730908 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 16 weeks (T16)
Number of subjects: 496
Study 10730908 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 400 mg/day for 1 week in every 4 weeks for 12 weeks (I3)
Number of subjects: 496
Study 10730908 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 400 mg/day for 1 week in every 4 weeks for 16 weeks (I4)
Number of subjects: 496
Study 8815279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aevit and glutaminic acid
Number of subjects: 54
Study 8815279 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy plus glucocorticoids
Number of subjects: 54
Study 1737529 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (6 separate monthly injections)
Number of subjects: 7
Study 1737529 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 insulin-dependent diabetic subjects treated with human insulin)
Number of subjects: 7
Study 6385785 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dexamethasone
Number of subjects: 86
Study 6385785 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 86
Study 31877840 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAPES intervention
Number of subjects: 0
Study 31877840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with FSH (75 IU)
Number of subjects: 738
Study 30137325 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation with Clomiphene Citrate (100 mg)
Number of subjects: 738
Study 27974124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gamma globulin (0.2 g/(kg · d)) combined with methylprednisolone
Number of subjects: 100
Study 27974124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gamma globulin (0.4 g/(kg · d)) combined with methylprednisolone
Number of subjects: 100
Study 25232263 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide 80 mg
Number of subjects: 93
Study 25232263 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide 40 mg
Number of subjects: 93
Study 25232263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 23983322 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapy
Number of subjects: 0
Study 23983322 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapy only
Number of subjects: 0
Study 21133786 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention to encourage hypertension self-management
Number of subjects: 0
Study 17418644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0
Study 17418644 — intervention group
Group type: COMPARATOR
Intervention: Other AEDs (Carbamazepine, Phenobarbital, Phenytoin, Valproate)
Number of subjects: 0
Study 15674409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation with Volume Guarantee (PSV-VG)
Number of subjects: 34
Study 15674409 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 34
Study 12503502 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol associated with valproate and clobazam
Number of subjects: 46
Study 10191742 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy knife
Number of subjects: 67
Study 10191742 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 67
Study 7779130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate for 3 months
Number of subjects: 234
Study 7779130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate for 6 months
Number of subjects: 234
Study 7779130 — intervention group
Group type: COMPARATOR
Intervention: Etidronate for 6 months
Number of subjects: 234
Study 2108990 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG supplementation
Number of subjects: 387
Study 2108990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 7284220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (6-8ml of 0.5% bupivacaine solution)
Number of subjects: 517
Study 7284220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (10-14ml of 0.25% bupivacaine solution)
Number of subjects: 517
Study 7284220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (6-8ml of 0.25% bupivacaine solution)
Number of subjects: 517
Study 7284220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 517
Study 7284220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 517
Study 7284220 — intervention group
Group type: COMPARATOR
Intervention: Group A, B, C
Number of subjects: 517
Study 7284220 — intervention group
Group type: COMPARATOR
Intervention: Group B, C
Number of subjects: 517
Study 29949455 — intervention group
Group type: EXPERIMENTAL
Intervention: MABT + treatment as usual (TAU)
Number of subjects: 217
Study 29949455 — intervention group
Group type: COMPARATOR
Intervention: Women's health education (WHE) + TAU (active control condition)
Number of subjects: 217
Study 29949455 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 217
Study 28590363 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐MPH (40 mg) with ethanol (0.6 g/kg)
Number of subjects: 14
Study 28590363 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH (20 mg) with ethanol (0.6 g/kg)
Number of subjects: 14
Study 28590363 — intervention group
Group type: COMPARATOR
Intervention: dl‐MPH (40 mg)
Number of subjects: 14
Study 28590363 — intervention group
Group type: COMPARATOR
Intervention: d‐MPH (20 mg)
Number of subjects: 14
Study 24809922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - aspirin and clopidogrel 75 mg/qd or ticlopidine 500 mg/bid
Number of subjects: 120
Study 24809922 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (ASA) - aspirin only
Number of subjects: 120
Study 22761759 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 single doses (3.75 µg hemagglutinin)
Number of subjects: 256
Study 22761759 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 double doses (7.5 µg hemagglutinin)
Number of subjects: 256
Study 22761759 — intervention group
Group type: COMPARATOR
Intervention: 1 dose (control group)
Number of subjects: 256
Study 20638380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (15 mg)
Number of subjects: 8
Study 20638380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (30 mg)
Number of subjects: 8
Study 20638380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (45 mg)
Number of subjects: 8
Study 20638380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mg)
Number of subjects: 8
Study 17621177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium ophthalmic solution 0.1%
Number of subjects: 61
Study 17621177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15176694 — intervention group
Group type: EXPERIMENTAL
Intervention: FRCUS (Functional Residual Capacity measured by ultrasonic flow meter)
Number of subjects: 23
Study 15176694 — intervention group
Group type: COMPARATOR
Intervention: FRCMS (Functional Residual Capacity measured by mass spectrometer)
Number of subjects: 23
Study 12120937 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature-delayed vaccination (first dose when weight of 2,000 g reached)
Number of subjects: 136
Study 12120937 — intervention group
Group type: COMPARATOR
Intervention: Premature vaccination (first dose within 24 h of birth)
Number of subjects: 136
Study 12120937 — intervention group
Group type: COMPARATOR
Intervention: Full-term vaccination (first dose within 24 h of birth)
Number of subjects: 136
Study 9824003 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP)
Number of subjects: 135
Study 9824003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 135
Study 7814825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 16
Study 7814825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2590584 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing device
Number of subjects: 0
Study 2590584 — intervention group
Group type: COMPARATOR
Intervention: Conventional rubber cup and paste method (Control)
Number of subjects: 0
Study 65040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 51
Study 65040 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 51
Study 65040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bleomycin and Radiotherapy
Number of subjects: 51
Study 31206768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual plasma molecular adsorption system (DPMAS) in addition to plasma exchange
Number of subjects: 162
Study 31206768 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (control group)
Number of subjects: 162
Study 31206768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DPMAS and control)
Number of subjects: 162
Study 31206768 — intervention group
Group type: EXPERIMENTAL
Intervention: DPMAS group
Number of subjects: 162
Study 28838644 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ileocaecal resection
Number of subjects: 143
Study 28838644 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 143
Study 25345427 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg/day with OC (levonorgestrel 150 μg + ethinyl estradiol 30 μg)
Number of subjects: 0
Study 25345427 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day with warfarin 30 mg/day
Number of subjects: 0
Study 23929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social influence
Number of subjects: 0
Study 23929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social influence
Number of subjects: 0
Study 23929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive herding
Number of subjects: 0
Study 21799044 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 quantitation
Number of subjects: 65
Study 21799044 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC quantitation
Number of subjects: 65
Study 19402191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 96
Study 19402191 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterjet dissection
Number of subjects: 96
Study 19402191 — intervention group
Group type: COMPARATOR
Intervention: Dissecting sealer
Number of subjects: 96
Study 19402191 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 96
Study 16395539 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy combined with intraoperative endoscopic sphincterotomy (LC-IOEST)
Number of subjects: 234
Study 16395539 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic exploration of the common bile duct (LCBDE)
Number of subjects: 234
Study 15372414 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 U subcutaneous epoetin alfa
Number of subjects: 153
Study 15372414 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 U subcutaneous epoetin alfa
Number of subjects: 153
Study 11335749 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T(4)) supplementation
Number of subjects: 200
Study 11335749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9274470 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (300 mg metronidazole, 500 mg amoxycillin, 250 mg clarithromycin, each given four times daily for two weeks)
Number of subjects: 100
Study 9274470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9274470 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics with H pylori clearance
Number of subjects: 100
Study 9274470 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics with H pylori eradication
Number of subjects: 100
Study 9274470 — intervention group
Group type: COMPARATOR
Intervention: Failure of H pylori clearance
Number of subjects: 100
Study 9274470 — intervention group
Group type: COMPARATOR
Intervention: Failure of H pylori eradication
Number of subjects: 100
Study 8519239 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal stents
Number of subjects: 62
Study 8519239 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene stents
Number of subjects: 62
Study 3319453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 18
Study 3319453 — intervention group
Group type: COMPARATOR
Intervention: Lactose
Number of subjects: 18
Study 29099236 — intervention group
Group type: EXPERIMENTAL
Intervention: Biting exercises (soft plastic roll for 5 min/d)
Number of subjects: 36
Study 29099236 — intervention group
Group type: COMPARATOR
Intervention: Control (no biting exercises)
Number of subjects: 36
Study 29099236 — intervention group
Group type: EXPERIMENTAL
Intervention: Biting exercises
Number of subjects: 36
Study 27411766 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyThink program (smartphone apps)
Number of subjects: 68
Study 27411766 — intervention group
Group type: COMPARATOR
Intervention: Control group (smartphone apps and small group counseling)
Number of subjects: 68
Study 25528166 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Supported Discharge (ESD) 1
Number of subjects: 306
Study 25528166 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Supported Discharge (ESD) 2
Number of subjects: 306
Study 25528166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled ESD groups
Number of subjects: 306
Study 25528166 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306
Study 22787176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment
Number of subjects: 456
Study 22787176 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 456
Study 21115933 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride 5 mg/day
Number of subjects: 60
Study 21115933 — intervention group
Group type: EXPERIMENTAL
Intervention: dutasteride 4 mg/day
Number of subjects: 60
Study 21115933 — intervention group
Group type: COMPARATOR
Intervention: no therapy (control)
Number of subjects: 60
Study 19049350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Mothers Postpartum (AMP) intervention including ten physical activity group sessions, eight healthy eating classes, and six telephone counseling sessions over a 9‐month period, along with motivational tools such as a workbook, pedometer, and sport stroller.
Number of subjects: 450
Study 19049350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Mothers Postpartum (AMP) intervention
Number of subjects: 450
Study 16719617 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe-sex with reminder intervention (bracelet)
Number of subjects: 196
Study 16719617 — intervention group
Group type: COMPARATOR
Intervention: Standard safe-sex intervention
Number of subjects: 196
Study 16719617 — intervention group
Group type: COMPARATOR
Intervention: Control (drinking and driving) intervention
Number of subjects: 196
Study 15053710 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral exemplarity attributes (just, brave, caring) identified through free-listing procedure in Study 1.
Number of subjects: 1206
Study 15053710 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality profiles for moral exemplars generated through prototypicality- and personality-rating procedures in Study 2.
Number of subjects: 1206
Study 15053710 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity-sorting procedure used to identify typologies of moral exemplarity in Study 3.
Number of subjects: 1206
Study 11165356 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 Hz filter setting with peak-to-peak measurement of P300
Number of subjects: 26
Study 11165356 — intervention group
Group type: COMPARATOR
Intervention: 0.01 Hz filter setting with base-peak measurement of P300
Number of subjects: 26
Study 11165356 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-peak measurement of P300
Number of subjects: 26
Study 11165356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-stimulus EEG baseline variability
Number of subjects: 26
Study 11165356 — intervention group
Group type: EXPERIMENTAL
Intervention: NEG seen only in 0.3 Hz channels
Number of subjects: 26
Study 9298796 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid growers
Number of subjects: 142
Study 9298796 — intervention group
Group type: COMPARATOR
Intervention: Slow growers
Number of subjects: 142
Study 8436729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-gender date-rape workshop
Number of subjects: 331
Study 8436729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to workshop)
Number of subjects: 331
Study 2872803 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg daily, administered alone or in combination with other antihypertensive agents)
Number of subjects: 0
Study 2872803 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (1 to 40 mg daily)
Number of subjects: 0
Study 31296043 — intervention group
Group type: EXPERIMENTAL
Intervention: SWCM+MISTT Website (group-3)
Number of subjects: 265
Study 31296043 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (group-1)
Number of subjects: 265
Study 31296043 — intervention group
Group type: COMPARATOR
Intervention: SWCM (group-2)
Number of subjects: 265
Study 30055583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 502
Study 26704693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF)
Number of subjects: 264
Study 26704693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF) with Ribavirin (RBV)
Number of subjects: 264
Study 26704693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF) without Ribavirin (RBV)
Number of subjects: 264
Study 24553033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BFM: 0.0625% bupivacaine + 2 μg/ml fentanyl + 2 mg morphine in 15 mL saline
Number of subjects: 120
Study 24553033 — intervention group
Group type: COMPARATOR
Intervention: Group BF: 0.1% bupivacaine + 2 μg/mL fentanyl in 15 mL saline
Number of subjects: 120
Study 21508267 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time wear for 3 months and thereafter at night (group A)
Number of subjects: 69
Study 21508267 — intervention group
Group type: COMPARATOR
Intervention: Full-time wear for 1 week and thereafter at night only (group B)
Number of subjects: 69
Study 21508267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 69
Study 20498395 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus Pegylated liposomal Doxorubicin (30 mg/m²) every 4 weeks
Number of subjects: 976
Study 20498395 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m²) every 3 weeks
Number of subjects: 976
Study 17645386 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 9
Study 15099916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.4 mg)
Number of subjects: 8
Study 15099916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.8 mg)
Number of subjects: 8
Study 15099916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (5 mg)
Number of subjects: 8
Study 15099916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (15 mg)
Number of subjects: 8
Study 15099916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.2 mg)
Number of subjects: 8
Study 15099916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12185409 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg IV)
Number of subjects: 12
Study 12185409 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 9824875 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 41
Study 9824875 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine titration (6-8 weeks)
Number of subjects: 41
Study 9824875 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotic drugs (APD)
Number of subjects: 41
Study 7663868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine sulfate 1 mg in normal saline 10 ml
Number of subjects: 40
Study 7663868 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular 0.5% bupivacaine 10 ml
Number of subjects: 40
Study 2680154 — intervention group
Group type: EXPERIMENTAL
Intervention: PQ 750 mg with NQ 25 mg
Number of subjects: 118
Study 2680154 — intervention group
Group type: EXPERIMENTAL
Intervention: PYR 600 mg with NQ 25 mg
Number of subjects: 118
Study 2680154 — intervention group
Group type: EXPERIMENTAL
Intervention: PYR 800 mg with NQ 40 mg
Number of subjects: 118